Oleoylethanolamide (OEA)

What the science says

• Appetite and body weight Limited evidence

  An RCT in obese people newly diagnosed with fatty liver reported modest reductions in weight and waist circumference alongside a calorie-restricted diet, and a later randomized trial found changes in self-reported dietary habits. Both were small, single-centre and used calorie restriction in both arms, so the independent effect of OEA is unclear.

• Satiety hormone response Limited evidence

  A fixed-sequence crossover study in a small group of adults found that a single dose of an OEA ingredient raised incretin hormone responses after a meal. It was an acute mechanistic study with no clinical endpoints.

• Blood lipids and glucose Limited evidence

  A randomized double-blind placebo-controlled trial in obese adults measured lipid profile and fasting blood sugar and found limited change. The evidence base is a handful of trials from a small number of research groups.

Dosage & safety

Scientific references

• Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes
  Tutunchi H, Ostadrahimi A, Saghafi-Asl M — Pharmacol Res, 2020
• The effect of Oleoylethanolamide supplementation on lipid profile, fasting blood sugar and dietary habits in obese people: a randomized double-blind placebo-control trial
  Ostadrahimi A, Khajebishak Y, Moradi F — BMC Endocr Disord, 2024
• Acute TRPTI™ (oleoylethanolamide) supplementation enhances incretin hormone responses: a fixed-sequence crossover study
  Briskey D, Pellow J, Viswanath P — Front Endocrinol (Lausanne), 2026

Related in Weight management

• L-Carnitine Moderate evidence
• MCT Oil Moderate evidence
• CLA (Conjugated Linoleic Acid) Limited evidence
• White Kidney Bean Extract Limited evidence
• Glucomannan Limited evidence
• Chitosan Limited evidence